Society for Translational Oncology


Highlights from STO's educational activities, including content associated with the Society and its journal The Oncologist. RSS Feed URL

Society for Translational Oncology navigateright Episode

IDH Inhibition in Acute Myeloid Leukemia – Emergence of a New Therapeutic Era

2HG, elevated in patients with IDH mutations, can also be measured in the serum and urine of affected patients, where it can serve as a biomarker of disease activity and therapeutic response. These advances triggered development of a new class of small molecule inhibitors of mutant IDH enzymes. After demonstrating promising anti-leukemic activity in animal models, phase 1 and 2 clinical trials of IDH inhibitors followed.  Trials of the IDH1 inhibitor ivosidenib and the IDH2 inhibitor enasidenib demonstrated single agent activity, response rate, transfusion independence, and long-term outcomes.

Video Overview:

Amir Fathi, MD 

MGH/Harvard Medical School

STO gratefully acknowledges educational grants in partial support of this activity from:
Agios Pharmaceuticals
Celgene Corporation
Novartis Pharmaceuticals Corp.
Pfizer Inc.